Diabetic kidney disease
Kidney disease caused by diabetes. The damage usually builds slowly over many years and most people have no symptoms, so it is found with blood and urine tests. About 1 out of 3 adults with diabetes has kidney disease.
Also called DKD · Diabetic Nephropathies · Diabetic nephropathy · Kidney disease of diabetes
- Condition
- In this atlas
Overview
Technical summary
MeSH descriptor D003928 (Diabetic Nephropathies). It sits between the diabetes pages and the chronic kidney disease page of this atlas. The evidence recorded here is descriptive; guideline links are added by a later step.
Burden
NIDDK names diabetes as the top cause of kidney disease and says that about 1 out of 3 adults with diabetes has kidney disease.
Applies to Adult Adults with diabetes, and diabetic kidney disease (NIDDK patient page)
Population, setting and follow-up
- Adults with diabetes, including those with diabetic kidney disease, as described by an NIDDK patient page and a MeSH scope note.
- Not stated; patient information page
- Not stated; United States federal health agency
- Adults
- Certainty method
- Not assessed
- Limitations
- An estimate on a patient-information page. The page cites a numbered reference that this atlas has not read, and it does not give the year or the country in the sentence.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (1)
-
Supports NIDDK: Diabetic Kidney Disease
- Locator
- What is diabetic kidney disease?, para 2
- How it applies
- NIDDK on how common kidney disease is in adults with diabetes.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
02b8aff57c0dbdc5f57973c176a0713030ac2b85389d2f74f0bf5a56df4482a5- Reuse basis
- The NIDDK copyright page (fetched 2026-10-30, sha256 977bc7ff58fd3f8dc5059eaa6d2b535a44f6a296df9cd68d19202916a71c2126, hash only) says the majority of information on the NIDDK site is copyright free and can be freely downloaded and reproduced, with NIDDK acknowledged as the source, and warns of a few exceptions such as documents sponsored with private companies. The raw page is committed in the atlas repository.
Claims and evidence
Context Adults with diabetes, and diabetic kidney disease (NIDDK patient page)
- Recipient
- Adult
- Population
- Adults with diabetes, including those with diabetic kidney disease, as described by an NIDDK patient page and a MeSH scope note.
- Care setting
- Not stated; patient information page
- Geography
- Not stated; United States federal health agency
- Life stage
- Adults
- Follow-up
- Not applicable (descriptive page)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
NIDDK says diabetic kidney disease is a type of kidney disease caused by diabetes. Kidney damage caused by diabetes usually occurs slowly, over many years, and most people with it do not have symptoms. Health care professionals use blood and urine tests to check for it. The MeSH scope note describes kidney injuries associated with diabetes mellitus that affect the glomerulus, arterioles, tubules and interstitium.
Applies to Adult Adults with diabetes, and diabetic kidney disease (NIDDK patient page)
- Certainty method
- Not assessed
- Limitations
- Patient-information and vocabulary sources. A patient-information or vocabulary source: it describes the condition and the direction of any risk. It gives no size for the risk, no time frame and no comparison group, and it is not clinical advice.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports MeSH scope note for descriptor D003928 (Diabetic Nephropathies)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note for the descriptor.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
869d608cceaac8ef1ae5800f81a39b1474a8757285e861fde69becdb7e75e18a- Reuse basis
- The NLM web policies page (fetched 2026-10-30, sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
-
Supports NIDDK: Diabetic Kidney Disease
- Locator
- What is diabetic kidney disease?, paras 1 and 5
- How it applies
- NIDDK definition and course.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
02b8aff57c0dbdc5f57973c176a0713030ac2b85389d2f74f0bf5a56df4482a5- Reuse basis
- The NIDDK copyright page (fetched 2026-10-30, sha256 977bc7ff58fd3f8dc5059eaa6d2b535a44f6a296df9cd68d19202916a71c2126, hash only) says the majority of information on the NIDDK site is copyright free and can be freely downloaded and reproduced, with NIDDK acknowledged as the source, and warns of a few exceptions such as documents sponsored with private companies. The raw page is committed in the atlas repository.
-
Supports NIDDK: Diabetic Kidney Disease
- Locator
- How can I tell if I have diabetic kidney disease?, paras 1 and 2
- How it applies
- NIDDK on symptoms and tests.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
02b8aff57c0dbdc5f57973c176a0713030ac2b85389d2f74f0bf5a56df4482a5- Reuse basis
- The NIDDK copyright page (fetched 2026-10-30, sha256 977bc7ff58fd3f8dc5059eaa6d2b535a44f6a296df9cd68d19202916a71c2126, hash only) says the majority of information on the NIDDK site is copyright free and can be freely downloaded and reproduced, with NIDDK acknowledged as the source, and warns of a few exceptions such as documents sponsored with private companies. The raw page is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Angiotensin receptor blockers (ARBs)
Applies to Mixed recipients People with hypertension (adults and pediatric patients 6 years and older), hypertension with left ventricular hypertrophy, or diabetic nephropathy in type 2 diabetes, as described in the US label of an ARB
Population, setting and follow-up
- Patients described in the indications section of the label: adults and pediatric patients 6 years of age and older with hypertension, patients with hypertension and left ventricular hypertrophy, and patients with type 2 diabetes, a history of hypertension, an elevated serum creatinine and proteinuria.
- Prescription medicine, as described in the US label
- United States (US drug label)
- Adults, and for hypertension also pediatric patients 6 years of age and older, as the label states
- Gestational age Not reported
- Postnatal age Not reported
The US label of COZAAR (losartan potassium tablets, Organon LLC, application NDA020386; the version dated 2026-01-20 in openFDA) calls the medicine an angiotensin II receptor blocker (ARB). It lists treating hypertension in adults and pediatric patients 6 years of age and older, reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. The label says there is evidence that the stroke benefit does not apply to Black patients. MeSH says the class antagonizes the angiotensin II type 1 receptor and that some of its members are used as antihypertensive agents.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's first list says children greater than 6 years old, while its detailed hypertension text says pediatric patients 6 years of age and older; the two were not reconciled. Other ARB labels list different uses. The label's contraindications, other warnings, interactions and dosing were not recorded; its boxed warning is recorded in a separate claim. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Losartan
Applies to Recipient not specified Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes
Population, setting and follow-up
- Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children); the stroke and diabetic nephropathy indications do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Adults for hypertension, as the passage read states; not stated for the other indications
- Gestational age Not reported
- Postnatal age Not reported
The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy, with the label stating that there is evidence this benefit does not apply to Black patients; and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 75
Record details
- Record id
cardio:diabetic-nephropathy- Content hash
85e4ada223d1ecd3e202b2da7515327eca2e7d024a7f82b7722fb4df49eadd9f